Clinical Trial: Hemodilution and Outcome in Cardiac Surgery
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Effect of Moderate Hemodilution During Cardiopulmonary Bypass on Postoperative Outcome Following Cardiac Surgery
Brief Summary:
An hematocrit of 21-25% is supposed to perform the best organ protection during cardiopulmonary bypass for cardiac surgery.
The investigators want to establish the best timing for a transfusion (in patients with a predicted low hematocrit during cardiopulmonary bypass) and the efficacy of preprocedural hemodilution (in patients with a predicted high hematocrit during cardiopulmonary bypass) in patients undergoing cardiac surgery.
Detailed Summary:
Sponsor: Università Vita-Salute San Raffaele
Current Primary Outcome: renal function
Original Primary Outcome: Same as current
Current Secondary Outcome:
- other organ damage
- prolonged mechanical ventilation, Intensive Care Unit (ICU) and hospital stay
- sepsis
- exitus
Original Secondary Outcome:
- other organ damage
- prolonged mechanical ventilation, ICU and Hospital stay
- sepsis
- exitus
Information By: Università Vita-Salute San Raffaele
Dates:
Date Received: August 11, 2006
Date Started: November 2006
Date Completion:
Last Updated: August 13, 2009
Last Verified: August 2009